Exenatide enhances cognitive performance and upregulates neurotrophic factor gene expression levels in diabetic mice. (21st March 2016)
- Record Type:
- Journal Article
- Title:
- Exenatide enhances cognitive performance and upregulates neurotrophic factor gene expression levels in diabetic mice. (21st March 2016)
- Main Title:
- Exenatide enhances cognitive performance and upregulates neurotrophic factor gene expression levels in diabetic mice
- Authors:
- Gumuslu, Esen
Mutlu, Oguz
Celikyurt, Ipek K
Ulak, Guner
Akar, Furuzan
Erden, Faruk
Ertan, Merve - Abstract:
- Abstract: Exenatide is a potent and selective agonist for the GLP‐1 (glucagon‐like peptide‐1) receptor. Recent studies are focused on the effects of GLP‐1 analogues on hippocampal neurogenesis, cognition, learning and memory functions. The aim of this study was to assess the effects of chronic exenatide treatment (0.1 μg/kg, s.c, twice daily for 2 weeks) on spatial memory functions by using the modified elevated plus maze (mEPM) test and emotional memory functions by using the passive avoidance (PA) test in streptozotocin/nicotinamide (STZ‐NA)‐induced diabetic mice. As the genes involved in neurite remodelling are among the primary targets of regulation, the effects of diabetes and chronic administration of exenatide on brain‐derived neurotrophic factor (BDNF) and cyclic adenosine monophosphate (cAMP) response element binding protein (CREB) messenger ribonucleic acid (mRNA) levels in the hippocampus of mice were also determined using quantitative real‐time polymerase chain reaction (RT‐PCR). This study revealed that in the mEPM and PA tests, type‐2 diabetes‐induced mice exhibited significant impairment of learning and memory which were ameliorated by GLP‐1 receptor agonist exenatide. Quantitative RT‐PCR revealed that CREB and BDNF gene expression levels were downregulated in diabetic mice, and these alterations were increased by exenatide treatment. Since, exenatide improves cognitive ability in STZ/NA‐induced diabetic mice and activates molecular mechanisms of memoryAbstract: Exenatide is a potent and selective agonist for the GLP‐1 (glucagon‐like peptide‐1) receptor. Recent studies are focused on the effects of GLP‐1 analogues on hippocampal neurogenesis, cognition, learning and memory functions. The aim of this study was to assess the effects of chronic exenatide treatment (0.1 μg/kg, s.c, twice daily for 2 weeks) on spatial memory functions by using the modified elevated plus maze (mEPM) test and emotional memory functions by using the passive avoidance (PA) test in streptozotocin/nicotinamide (STZ‐NA)‐induced diabetic mice. As the genes involved in neurite remodelling are among the primary targets of regulation, the effects of diabetes and chronic administration of exenatide on brain‐derived neurotrophic factor (BDNF) and cyclic adenosine monophosphate (cAMP) response element binding protein (CREB) messenger ribonucleic acid (mRNA) levels in the hippocampus of mice were also determined using quantitative real‐time polymerase chain reaction (RT‐PCR). This study revealed that in the mEPM and PA tests, type‐2 diabetes‐induced mice exhibited significant impairment of learning and memory which were ameliorated by GLP‐1 receptor agonist exenatide. Quantitative RT‐PCR revealed that CREB and BDNF gene expression levels were downregulated in diabetic mice, and these alterations were increased by exenatide treatment. Since, exenatide improves cognitive ability in STZ/NA‐induced diabetic mice and activates molecular mechanisms of memory storage in response to a learning experience, it may be a candidate for alleviation of mood and cognitive disorder. … (more)
- Is Part Of:
- Fundamental & clinical pharmacology. Volume 30:Number 4(2016:Aug.)
- Journal:
- Fundamental & clinical pharmacology
- Issue:
- Volume 30:Number 4(2016:Aug.)
- Issue Display:
- Volume 30, Issue 4 (2016)
- Year:
- 2016
- Volume:
- 30
- Issue:
- 4
- Issue Sort Value:
- 2016-0030-0004-0000
- Page Start:
- 376
- Page End:
- 384
- Publication Date:
- 2016-03-21
- Subjects:
- BDNF -- CREB -- exenatide -- memory -- type‐2 diabetes
Pharmacology -- Periodicals
615.1 - Journal URLs:
- http://www.blackwell-synergy.com/member/institutions/issuelist.asp?journal=fcp ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1472-8206 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/fcp.12192 ↗
- Languages:
- English
- ISSNs:
- 0767-3981
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4056.033000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 2047.xml